POMP trial: information for patients
Why are we investigating kidney perfusion?
Kidney transplantation is a successful treatment for end-stage renal disease. The standard methods for storing and transporting kidneys for transplantation are to either store them in a cold solution or to perfuse them with a cold perfusion solution on ice. It has been shown in clinical trials in recent years, that connecting the donor kidney with a machine and perfuse it with a cooled organ preservation solution improves kidney function once transplanted in the recipient. This effect was best demonstrated in kidneys donated by expanded criteria donors (ECD), which are donors of older age and with comorbidities such as hypertension. Improving organ function in these kidneys would increase the number of kidneys that can be successfully transplanted and decrease the number of patients on the waiting list.
Experimental models have also shown that it is sufficient to perform machine perfusion for a short period of time (i.e. immediately prior to implantation) before reperfusion of the organ. This would also show a benefit to logistics, as kidneys would only need to be perfused at the transplantation centre of the recipient.
What are our aims?
The aim of this study is to assess whether machine perfusion performed immediately prior to implantation and after transport in cold storage solution will reduce damage, decrease ischemia-reperfusion injury and improve graft survival and function in ECD kidneys.
How is the study carried out?
In this study two groups will be compared: a control group (static cold storage), which is the standard preservation method, and an interventional group (hypothermic oxygenated machine perfusion after static cold storage). The COPE-POMP trial is carried out in academic hospitals with an active adult kidney transplant programme in Germany, Belgium, the Netherlands, United Kingdom and their donor hospitals. It went live in all centres in December 2014. The trial will randomise a total of 262 kidneys, half of which will be cold stored and half of which will be machine perfused prior to implantation. Trial outcomes will be reported, one year after the last kidney has been included in the trial. Beyond kidney survival, organ function, as well as quality of life of the recipient will be assessed and evaluated.
Where can I get more information?
For more information, please contact Dr Peri Kocabayoglu through Peri.Kocabayoglu@uk-essen.de.